Striverdi Respimat

Chemical Nameolodaterol
Dosage FormInhalation spray (oral; 2.5 mcg)
Drug ClassReceptor agonists
SystemRespiratory
CompanyBoehringer Ingelheim Pharmaceuticals
Approval Year2014

Indication

  • For the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Last updated on 4/20/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Striverdi Respimat (olodaterol) Prescribing Information 2014Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT
Document TitleYearSource
Romanian clinical guideline for diagnosis and treatment of COPD.2020Journal of International Medical Research